Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 15/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 12/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25412117 | 1.00 | NOS2 (0.46) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL26313486 | 0.89 | NOS2 (0.46) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL25409866 | 0.88 | NOS2 (0.57) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL25411357 | 0.88 | NOS2 (0.57) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL25413459 | 0.85 | SLC6A4 (0.58) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL25413462 | 0.85 | SLC6A4 (0.58) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL26313493 | 0.84 | SLC6A4 (0.50) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL26313488 | 0.83 | SLC6A4 (0.46) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL25411241 | 0.82 | SLC6A4 (0.45) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL25413663 | 0.82 | SLC6A2 (0.45) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | NOS1, NOS3, NOS2 | NOS2 3/4885SLC6A4 841/4885CYP2D6 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.